Molecular expression of epitopes recognized by monoclonal antibodies HMFG-1 and HMFG-2 in human breast cancers: Diversity, variability and relationship to prognostic factors

1986 ◽  
Vol 38 (1) ◽  
pp. 89-96 ◽  
Author(s):  
J. E. Turnbull ◽  
A. D. Baildam ◽  
Diana M. Barnes ◽  
A. Howell
Keyword(s):  
Monoclonal Antibodies ◽  
Prognostic Factors ◽  
Breast Cancers ◽  
Human Breast ◽  
Molecular Expression

scholarly journals EVALUATIN OF ErbB-2 PROTEIN IN TISSUE EXTRACT COMPARED WITH OTHER PROGNOSTIC FACTORS IN HUMAN BREAST CANCERS

1997 ◽  
Vol 58 (1) ◽  
pp. 8-11
Author(s):  
Yoshiaki MAEDA ◽  
Masami OGITA ◽  
Yuusuke IKEDA ◽  
Kazutomo KIKUCHI ◽  
Tatsuro YAMAGUCHI
Keyword(s):  
Prognostic Factors ◽  
Tissue Extract ◽  
Breast Cancers ◽  
Human Breast

Mechanisms of resistance to endocrine therapies for breast cancer

2012 ◽  
Vol 9 (2) ◽  
Author(s):  
Pierre Heudel ◽  
Paul Vilquin ◽  
Olivier Tredan ◽  
Isabelle Ray-Coquard ◽  
Jean-Paul Guastalla ◽  
...  
Keyword(s):  
Public Health ◽  
Breast Cancer ◽  
Prognostic Factors ◽  
Molecular Mechanisms ◽  
Health Concern ◽  
Breast Cancers ◽  
Human Breast ◽  
Mechanisms Of Resistance ◽  
Public Health Concern ◽  
Clinical Models

AbstractBreast cancer is the most frequently diagnosed cancer in women and 70% of the cases are hormone-dependent. The presence of ERα is one of the most important prognostic factors predictive of response to endocrine therapy in human breast cancers. Resistance to endocrine therapies has become a major public health concern and it appears essential to understand the mechanisms underlying this phenomenon. This review provides insights into the molecular mechanisms associated with resistance to endocrine therapies and presents the different strategies currently developed in pre-clinical models to overcome this resistance.

scholarly journals MRCKα Is Dispensable for Breast Cancer Development in the MMTV-PyMT Model

Cells ◽  
2021 ◽  
Vol 10 (4) ◽  
pp. 942
Author(s):  
Mei Qi Kwa ◽  
Rafael Brandao ◽  
Trong H. Phung ◽  
Jianfeng Ge ◽  
Giuseppe Scieri ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression Signature ◽  
Genomic Analysis ◽  
Cancer Development ◽  
Breast Cancer Cell Lines ◽  
Normal Mammary Gland ◽  
Breast Cancers ◽  
Human Breast ◽  
Breast Cancer Development

MRCKα is a ubiquitously expressed serine/threonine kinase involved in cell contraction and F-actin turnover, which is highly amplified in human breast cancer and part of a gene expression signature for bad prognosis. Nothing is known about the in vivo function of MRCKα. To explore MRCKα function in development and in breast cancer, we generated mice lacking a functional MRCKα gene. Mice were born close to the Mendelian ratio and showed no obvious phenotype including a normal mammary gland formation. Assessing breast cancer development using the transgenic MMTV-PyMT mouse model, loss of MRCKα did not affect tumor onset, tumor growth and metastasis formation. Deleting MRCKα and its related family member MRCKβ in two triple-negative breast cancer cell lines resulted in reduced invasion of MDA-MB-231 cells, but did not affect migration of 4T1 cells. Further genomic analysis of human breast cancers revealed that MRCKα is frequently co-amplified with the oncogenes ARID4B and AKT3 which might contribute to the prognostic value of MRCKα expression. Collectively, these data suggest that MRCKα might be a prognostic marker for breast cancer, but probably of limited functional importance.

Analysis of the aromatase cytochrome P450 gene in human breast cancers

1994 ◽  
Vol 13 (3) ◽  
pp. 331-337 ◽  
Author(s):  
P Sourdaine ◽  
M G Parker ◽  
J Telford ◽  
W R Miller
Keyword(s):  
Cytochrome P450 ◽  
Breast Cancers ◽  
Human Breast ◽  
Cytochrome P450 Gene ◽  
P450 Gene

MONOCLONAL ANTIBODIES AS PROBES OF HUMAN BREAST DISORDERS

1983 ◽  
Vol 417 (1 Oncodevelopme) ◽  
pp. 251-261 ◽  
Author(s):  
Munro Neville A ◽  
C. Foster ◽  
H. Redding ◽  
R. C. Coombes
Keyword(s):  
Monoclonal Antibodies ◽  
Human Breast
Sign in / Sign up

Export Citation Format

Share Document